Surefire Medical's Infusion Technology Studied for Treatment of Primary Liver Cancer
March 8, 2017—Surefire Medical, Inc. announced that clinical data from a retrospective case-controlled comparison showed that the use of Surefire infusion technology achieved a 79% objective response rate in the treatment of primary liver cancer (hepatocellular carcinoma [HCC]) in transarterial chemoembolization procedures versus 37% with a standard microcatheter. The study was presented at the Society for Interventional Radiology (SIR) 2017 annual scientific meeting in Washington, DC.
Alexander Y. Kim, MD, who is Assistant Professor of Radiology at Georgetown University Medical Center (GUMC), conducted a review of patient records from GUMC’s clinical partner, MedStar Georgetown University Hospital in Washington, DC.
According to Surefire Medical, the case-controlled study was performed on a total of 38 patients, with 19 patients in each arm. Selection of patients included in the study was based on similar tumor size, location, laterality, Child-Pugh score of the severity of chronic liver disease, and underlying etiology of HCC.
The study found that patients treated with the Surefire infusion system demonstrated a statistically significant improvement in disease response rate compared to those undergoing treatment with a standard end-hole microcatheter.
The company noted that in a pilot study published by Alexander S. Pasciak, PhD, et al in Journal of Vascular and Interventional Radiology in 2015, the Surefire infusion system was shown to increase tumor uptake by 68% and reduce treatment delivered to healthy tissue by 58% when compared to a standard microcatheter when treating multiple cancers of the liver.
Additional clinical research conducted by Dr. Kim at Georgetown and presented at the last year's 2016 SIR annual meeting showed that the Surefire technology effectively delivered therapy in the treatment of HCC with an 80% complete tumor response and 93% objective tumor response. A prospective, comparative evaluation is now underway to validate the preliminary findings, stated Surefire Medical.